The Cholera Vaccines Market is expanding rapidly due to the rising incidence of cholera outbreaks, particularly in low- and middle-income countries with limited access to clean water and sanitation. Governments and global health organizations are increasing immunization campaigns to prevent epidemic outbreaks, especially in disaster-prone and conflict-affected regions. Growing awareness about oral cholera vaccines and improved distribution networks are further strengthening demand. In addition, international stockpiling initiatives and emergency vaccination programs are significantly contributing to market growth.

What Is the Cholera Vaccines Market Size and Forecast?

The global Cholera Vaccines Market size reached USD 135.09 Million in 2025, driven largely by the growing demand for Dukoral and other oral cholera vaccines. The market is projected to grow at a CAGR of 12.00% between 2026 and 2035, reaching approximately USD 419.57 Million by 2035. This strong double-digit growth reflects increasing public health investments, rising travel-related vaccinations, and expanded immunization coverage in endemic regions.

Cholera Vaccines Market Share by Product and End User

The Cholera Vaccines Market share is segmented by product into Dukoral, Shanchol, Vaxchora, and others. Among these, Dukoral holds a notable share due to its established presence in travel medicine and routine immunization programs. Shanchol is widely used in mass vaccination campaigns in developing countries, while Vaxchora is primarily recommended for travelers to high-risk areas.

By end user, hospitals and clinics account for the largest share, supported by national vaccination drives and outbreak response programs. Research and academic laboratories also contribute to the market by supporting vaccine development and clinical studies.

Request sample report Explore

Cholera Vaccines Market Trends and Regional Outlook

Key Cholera Vaccines Market trends include increased global stockpiling, expansion of oral vaccine production capacity, and partnerships between governments and vaccine manufacturers. The shift toward single-dose regimens and cost-effective vaccine options is also influencing procurement strategies.

Regionally, Asia Pacific and Africa represent significant growth opportunities due to high disease burden. North America and Europe contribute through travel vaccination demand and funding support for global immunization initiatives. Latin America and the Middle East and Africa are also witnessing gradual market expansion.

Major companies operating in the market include Sanofi-aventis Groupe, Emergent BioSolutions Inc., Valneva SE, GlaxoSmithKline plc., Johnson & Johnson Services Inc., and Merck & Co. Inc.